LY-3475070 is a selective kappa opioid receptor (KOR) antagonist being investigated primarily for its potential in treating psychiatric and neurological disorders. It has shown promise in preclinical studies for modulating stress-related behaviors and depressive symptoms without the side effects commonly associated with traditional antidepressants. Due to its ability to cross the blood-brain barrier effectively, it is being explored as a therapeutic agent in mood disorders, including major depressive disorder and anxiety. Additionally, its KOR antagonism may help reduce dysphoria and anhedonia, making it a candidate for conditions involving reward pathway dysfunction. Research is ongoing to evaluate its efficacy in substance use disorders, where KOR activation plays a role in drug-seeking behavior and relapse. Its development highlights a targeted approach to mental health treatment with improved tolerability and faster onset of action.